We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

99 hedge funds and large institutions have $664M invested in G1 Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 20

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

5% more funds holding

Funds holding: 94 → 99 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less capital invested

Capital invested by funds: $863M → $664M (-$199M)

87% less call options, than puts

Call options by funds: $640K | Put options by funds: $5.01M

Holders
99
Holders Change
+5
Holders Change %
+5.32%
% of All Funds
2.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
42
Reduced
20
Closed
15
Calls
$640K
Puts
$5.01M
Net Calls
-$4.37M
Net Calls Change
-$4.53M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.5M
2
CS
Candriam SCA
Luxembourg
+$9.54M
3
RPAM
Rhenman & Partners Asset Management
Sweden
+$8.24M
4
Invesco
Invesco
Georgia
+$6.55M
5
Millennium Management
Millennium Management
New York
+$4.98M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$14.8M
2
State Street
State Street
Massachusetts
-$5.93M
3
Marshall Wace
Marshall Wace
United Kingdom
-$5.81M
4
JP Morgan Chase
JP Morgan Chase
New York
-$5.8M
5
IBT
International Biotechnology Trust
United Kingdom
-$4.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Tang Capital Management
California
$3.42M -$1.58M -50,000 -25%
N
27
Nuveen
North Carolina
$3.04M +$601K +19,060 +17%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.01M -$90.4K -2,867 -2%
BBA
29
Baker Bros. Advisors
New York
$2.9M – – –
AA
30
ALPS Advisors
Colorado
$1.71M -$112K -3,560 -5%
Allianz Asset Management
31
Allianz Asset Management
Germany
$1.68M +$559K +17,741 +35%
TCM
32
Tuttle Capital Management
Connecticut
$1.6M +$1.39M +44,173 New
Ameriprise
33
Ameriprise
Minnesota
$1.55M -$279K -8,863 -12%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$1.53M +$1.12M +35,662 +113%
UBS Group
35
UBS Group
Switzerland
$1.52M +$1.56M +49,598 +291%
DCM
36
Driehaus Capital Management
Illinois
$1.25M +$1.73M +54,821 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$1.2M +$21.2K +671 +1%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$1.16M +$624K +19,800 +64%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$1.12M -$262K -8,296 -14%
Swiss National Bank
40
Swiss National Bank
Switzerland
$1.12M +$22.1K +700 +1%
AllianceBernstein
41
AllianceBernstein
Tennessee
$1.08M – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.04M +$56.2K +1,783 +4%
CAM
43
Cormorant Asset Management
Massachusetts
$1.02M +$31.5K +1,000 New
PPA
44
Parametric Portfolio Associates
Washington
$998K +$964K +30,577 +231%
TD Asset Management
45
TD Asset Management
Ontario, Canada
$942K +$265K +8,392 +25%
BC
46
Birchview Capital
Vermont
$911K – – –
S
47
SignatureFD
Georgia
$864K – – –
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$852K +$85.1K +2,700 +8%
BWA
49
BDO Wealth Advisors
Florida
$803K – – –
Squarepoint
50
Squarepoint
New York
$749K +$822K +26,067 +383%
1
2
3 4 5

GTHX Hedge Fund Activity: Q3 2019 in Review

99 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2019, worth a combined $664M — down 23% from $863M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new GTHX positions and 15 closed out — a net gain of 6 holders — while 42 added to existing stakes and 20 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $12.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $14.8M sold.

  • 99 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2019, up from 94 in Q2 2019.
  • Funds reported $664M of G1 Therapeutics, Inc. Common Stock stock for Q3 2019, down 23% quarter-over-quarter.
  • 21 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2019 and 15 closed out, a net change of +6 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2019 was T. Rowe Price Associates, an estimated $12.5M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2019 was RA Capital Management, an estimated $14.8M sold.

Based on aggregated 13F filings for Q3 2019.